



Primary Progressive Multiple Sclerosis Evolving from Radiologically Isolated Syndrome

This is the peer reviewed version of the following article:

Original:

Kantarci, O.H., Lebrun, C., Siva, A., Keegan, M.B., Azevedo, C.J., Inglese, M., et al. (2016). Primary Progressive Multiple Sclerosis Evolving from Radiologically Isolated Syndrome. ANNALS OF NEUROLOGY, 79(2), 288-294 [10.1002/ana.24564].

Availability:

This version is available <http://hdl.handle.net/11365/1003841> since 2017-01-27T11:17:49Z

Published:

DOI:10.1002/ana.24564

Terms of use:

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)

Primary Progressive MS evolving from Radiologically Isolated Syndrome

Orhun H. Kantarci, M.D.¹, Christine Lebrun, M.D., Ph.D.², Aksel Siva, M.D.³, Mark B. Keegan, M.D.¹, Christina J. Azevedo, M.D. MPH⁴, Matilde Inglese, M.D.⁵, Mar Tintoré, M.D.⁶, Braeden D. Newton, B.S.⁷, Francoise Durand-Dubief, M.D.⁸, Maria Pia Amato, Ph.D.⁹, Nicola De Stefano, M.D.¹⁰, Maria Pia Sormani, Ph.D.¹¹, Daniel Pelletier, M.D.⁴, Darin T. Okuda, M.D.⁷

¹ Mayo Clinic College of Medicine. Department of Neurology. Rochester, Minnesota, U.S.A.

² Hôpital Pasteur, Service de Neurologie. Nice, France

³ University of Istanbul. Department of Neurology, Cerrahpasa School of Medicine. Istanbul, Turkey

⁴ Keck School of Medicine of the University of Southern California. Department of Neurology. Multiple Sclerosis Center. Los Angeles, California, U.S.A.

⁵ Mt. Sinai School of Medicine. New York, New York, U.S.A.

⁶ MS Center of Catalunya Cemcat, Vall d'Hebron Hospital, Barcelona, Spain

⁷ University of Texas Southwestern Medical Center, Department of Neurology & Neurotherapeutics, Clinical Center for Multiple Sclerosis, Multiple Sclerosis and NeuroImmunology Imaging Program, Dallas, Texas, U.S.A

⁸ Service de Neurologie. Hôpital Neurologique. 59 bd Pinel, 69000 BRON. France

⁹ University of Florence, Department of Neurology, Florence, Italy.

¹⁰ University of Siena, Department of Neurology, Neurosurgery & Behavioral Sciences. Siena, Italy

¹¹ University of Genoa, Department of Health Sciences (DISSAL). Genoa, Italy

Submitted on behalf of the Radiologically Isolated Syndrome Consortium (RISC), Société Francophone de la Sclérose en Plaques (SFSEP) and Observatoire Français de la Sclérose En Plaques (OFSEP)

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article', doi: 10.1002/ana.24564

Key words: radiologically isolated syndrome, multiple sclerosis, primary progressive MS, progressive MS, prediction

Running title: Pre-progressive phase of primary progressive MS

#of characters (title): 69

of characters (running title):48, # of words (abstract): 250 # of words (text): 2649,

of figures: 4

of tables (manuscript): 1

of tables (supplementary): 2

Correspondence to:

Orhun H. Kantarci, M.D.

Department of Neurology, Mayo Clinic and Foundation

200 First Street, SW, Rochester, MN 55905

Phone: 507-284-4234

Fax: 507-266-4419

e-mail: kantarci.orphun@mayo.edu

ABSTRACT:

Objective: To evaluate the pre-progressive phase in subjects with radiologically isolated syndrome (RIS) who evolve to primary progressive MS (PPMS).

Methods: A multicenter RIS cohort was previously established. Demographic, clinical and radiological characteristics of subjects with RIS that evolved directly to PPMS were compared to those that developed a relapsing from onset disease (clinically isolated syndrome (CIS) or relapsing-remitting MS), and were also compared to two other population-based and clinic-based PPMS cohorts.

Results: Of the 453 subjects with RIS, 128 evolved to symptomatic MS during the follow-up (113 developed a first acute clinical event consistent with CIS/MS, 15 evolved to PPMS). PPMS prevalence (11.7%) and onset age (mean \pm SD; 49.1 ± 12.1) in the RIS group was comparable to other PPMS populations ($p > 0.05$). Median time to PPMS was 3.5 years (range: 1.6-5.4). RIS evolved to PPMS more commonly in men ($p = 0.005$) and at an older age ($p < 0.001$) when compared to CIS/MS, independent of follow-up duration. Subjects who evolved to PPMS had more spinal cord lesions (100%) before symptomatic evolution than those that developed CIS/MS (64%) and those that remained asymptomatic (23%) within the follow-up period ($p = 0.005$). Other MRI characteristics in the pre-progressive phase of PPMS were indistinguishable from CIS/MS.

Interpretation: Subjects with RIS evolve to PPMS at the same frequency as expected from general MS populations in an age dependent manner. Besides age unequivocal presence of spinal cord lesions and being male predicts evolution to PPMS. Our findings further suggest that RIS is biologically part of the MS spectrum.

INTRODUCTION:

Multiple sclerosis (MS) is a heterogeneous immune-mediated central nervous system (CNS) demyelinating disease that is punctuated by four phases: i) a phase of MS risk, ii) an asymptomatic-preclinical phase, iii) a relapsing-remitting phase (RRMS) and iv) a progressive phase. In the latest revision of the diagnostic criteria for MS, asymptomatic sub-clinical activity, appreciated via magnetic resonance imaging (MRI), is proposed to fulfill both spatial and temporal dissemination requirements for MS.¹⁻³ Therefore, inactivity within all phases is implied based on the absence of both new MRI and clinical events suggestive of acute inflammatory demyelination within the last year.⁴

Many patients with MS, who are evaluated for the first time for a symptomatic syndrome suggestive of inflammatory-demyelinating disease, already have clinically silent lesions on MRI suggesting an asymptomatic prodrome of unknown duration. The early manifestations of CNS demyelination may also be appreciated in subjects who have an MRI as healthy control subjects for the investigation of symptoms that are incongruent with an inflammatory demyelinating syndrome. Such subjects are described as having radiologically isolated syndrome (RIS), when 3 or 4 of the 4 radiological criteria for dissemination in space are met.⁵⁻⁷ These subjects may remain asymptomatic, or develop clinically isolated syndrome (CIS) and RRMS.^{8,9} Therefore, RIS may represent the earliest presentation of MS during the asymptomatic-preclinical phase. We recently reported asymptomatic to symptomatic evolution typical of demyelination in 34% of subjects with RIS within the first 5 years of follow-up.¹⁰ Risk factors for developing a first symptomatic event included male sex, younger age at the time of RIS diagnosis (< 37 years), and the presence of spinal cord lesions.¹⁰

The progressive phase of MS is currently classified by the temporal relationship between clinical phenotypes of symptomatic relapses and progression.¹¹ Secondary progressive MS (SPMS) follows RRMS, while single attack progressive MS (SAPMS) occurs after a single demyelinating event - CIS.¹² In primary progressive MS (PPMS), a decline in physical abilities occurs without preceding relapses. Pure PPMS excluding SAPMS, a group that could have been included in the PPMS definition in the past, constitutes about 10% of all MS patients at presentation.^{13, 14} While PPMS generally is accepted to be related to spinal-cord dominant form of MS¹⁵, many PPMS patients present with multiple brain or spinal cord lesions similar to that of bout-onset progressive MS (SPMS + SAPMS), suggesting a protracted asymptomatic-preclinical phase of MS. Several recent studies have also established that PPMS, SAPMS and SPMS are strikingly similar in terms of age at progressive disease course onset.^{14, 16, 17} It is likely that PPMS and other bout-onset forms of progressive MS are presentations of the same biology of a progressive phenotype, differentiated only by the resistance to acute symptomatic manifestations as relapses.

We hypothesize that subclinical disease activity in PPMS during the pre-progressive phase is similar to that of other MS patients. For SPMS, the pre-progressive phase is better defined in natural history studies involving those with RRMS. It is predicted that approximately 25% of RRMS patients will never evolve to SPMS, highlighting disease heterogeneity.¹⁴ An unbiased natural history study aimed at investigating the temporal profile of disease activity from incidentally identified radiological anomalies to the development of non-acute symptoms typical for the onset of PPMS is difficult. A population-based imaging effort to identify such subjects in the pre-progressive phase of PPMS is simply resource prohibitive. We present demographic and imaging findings collected during the pre-progressive phase from subjects prospectively followed

and enrolled in a multinational RIS cohort who developed PPMS, in comparison to those who experienced a first acute symptomatic demyelinating episode.

Accepted Article

METHODS:*Ethical statement:*

All data were collected with written informed consent to access medical information from all patients under a protocol approved by appropriate institutional review boards from each center.

Definition of terms:

RIS was defined according to the previously established criteria.⁷ Outcome of symptomatic evolution was assigned to any individual that developed a clinical syndrome that could not be explained by any neurological disease other than a CNS demyelinating disorder. In those subjects with symptomatic evolution as an acute demyelinating event, a diagnosis of CIS/MS was assigned according to established criteria.¹⁻³ In those subjects with symptomatic evolution as insidious neurological worsening for at least a 12-month period, a diagnosis of PPMS was assigned according to the established criteria.³

Study populations:

Data were ascertained from three previously published cohorts; An RIS cohort that originated from 22 clinical sites within 5 countries (n=453)¹⁰; a population-based cohort of all MS patients from Olmsted County, MN with a longitudinal follow-up of more than 20 years (n=210)^{14, 18, 19} and a recently established large clinic-based cohort of progressive MS patients (n=754).^{14, 20}

Data collection:

MRI data was collected as previously described.¹⁰ Information on lesions location, number and enhancement characteristics were described and coded for the brain and spinal cord MRIs when available according to diagnostic criteria.^{5, 6} Cerebrospinal fluid information was coded as

positive when patients had presence of either oligoclonal bands or elevated IgG index according to local standards at each clinical laboratory.

Data analyses:

We compared demographic and clinical features in different populations by χ^2 , Fischer's exact test or Student-T tests as appropriate to the variable. We studied probability of evolution from RIS to PPMS vs. RIS to CIS/MS according to age and time by the Kaplan-Meier and Cox regression analyses.

Accepted Article

RESULTS:*Prevalence of evolution to PPMS among subjects with RIS:*

Of the 453 subjects with RIS identified between multiple centers¹⁰, 128 developed symptomatic MS (Figure-1). Of these 113 developed a first acute clinical event related to CNS demyelination consistent with CIS/MS diagnosis while 15 evolved to PPMS. Thus, among subjects with RIS who developed a symptomatic demyelinating syndrome, the prevalence of PPMS was 11.7%.

Demographic, Clinical and MRI characteristics of subjects who evolved to PPMS:

In subjects who evolved to PPMS, 6 were women, median age (range) at RIS was 43.3 (range: 20-66) years, median duration of follow-up was 5.8 (range: 1.1-18.0) years, and median time to conversion was 3.5 (range: 1.6-5.4) years.

The reasons for obtaining the initial MRI leading to a diagnosis of RIS were as follows; primary headache (n=4), trauma (n=5), low back pain (n=1), radiculopathy (n=1), history of childhood epilepsy (n=1), non-neurological spells (n=1), non-central hearing impairment (n=1) and malignancy screening (n=1).

The initial MRI screening could have been one of various spinal cord levels. However, identification of a demyelinating lesion at any level led to an additional brain MRI fulfilling the previously established RIS criteria in all 15 subjects. Also an initial MRI may have been done

without gadolinium but following MRIs establishing the diagnosis of RIS could have been completed with gadolinium.

At the time of first brain MRI fulfilling RIS criteria, all 15 subjects had periventricular lesions (8/15 had >10 lesions; 5/15 had 6-10 lesions, 2/15 had 1-6 lesions), 13 subjects had subcortical / juxta-cortical lesions (3/13 had >10 lesions, 5/13 had 6-10 lesions, 7/13 had 1-6 lesions) and 9 subjects had infra-tentorial lesions (0/9 had >10 lesions, 1/9 had 6-10 lesions, 8/9 had 1-6 lesions).

Only 12 of 15 subjects had a spinal cord MRI at the time of first brain MRI or before conversion to symptomatic MS. All 12 subjects had cervical cord lesions (3/12 had >10 lesions, 5/12 had 6-10 lesions, 4/12 had 1-6 lesions) while 9 of 11 subjects who had thoracic cord MRI had thoracic cord lesions (2/9 had >10 lesions, 0/9 had 6-10 lesions, 7/9 had 1-6 lesions).

In Figure-2, we illustrate the typical time-course with imaging findings from a subject followed for 9 years with a diagnosis of RIS prior to developing neurological symptoms related to progressive myelopathy/ataxia and fulfilling a diagnosis of PPMS.

Comparison of Demographic, Clinical and MRI characteristics of subjects who evolved to PPMS versus those that developed CIS/MS:

Subjects who evolved to PPMS were more commonly men ($p=0.005$) when compared to those that developed CIS/MS (Table-1). Both the median age at RIS ($p<0.001$) and median age at symptomatic evolution ($p<0.001$) was older by approximately 10 years for subjects that evolved to

PPMS than those that developed CIS/MS. While evolution to PPMS happened at an older age, the observation did not appear to be related to follow-up time after RIS diagnosis ($p=0.21$) (Figure-3).

When spinal cord MRIs were available before conversion to symptomatic MS, the presence of spinal cord lesions at the time of first RIS MRI highly correlated with evolution of symptomatic MS in the whole group of RIS subjects (HR=3.33, 95%CI= 2.22-4.99, $p<0.001$). However, there was also a highly significant difference in the presence of spinal cord lesions between subjects that evolved to PPMS (100%) and those that developed CIS/MS (64%) ($p=0.005$) (Table-1).

On baseline brain MRI studies, if gadolinium was administered, at least one enhancing lesion was observed in 76 of 277 subjects that remained asymptomatic (27.4%), 30 of 91 that developed CIS/MS (33.0%) and 2 of 13 that evolved to PPMS (15.4%) ($p=0.32$). On baseline spinal cord MRIs, if gadolinium was administered, 14 of 255 subjects that remained asymptomatic (5.5%), 25 of 101 that developed CIS/MS (24.8%) and 6 of 15 that evolved to PPMS (40.0%) had at least one enhancing lesion ($p<0.001$). However, when the enhancing spinal cord lesions were considered as a fraction of total spinal cord lesions and compared among subjects that remained asymptomatic, those that developed CIS/MS and those that evolved to PPMS, the results were not significant ($p>0.05$). There was also no specific difference among subjects that developed CIS/MS and those that evolved to PPMS (Table-1).

Comparison of Demographic, Clinical characteristics of subjects with RIS who evolved to PPMS with other populations of PPMS:

The mean age at onset of PPMS ($n=15$; mean \pm SD; 49.1 ± 12.1) in the RIS cohort was comparable to the population-based patients with PPMS ($n=15$; mean \pm SD; 41.1 ± 11.6)

($p=0.076$), and the clinic-based patients with PPMS ($n=308$; mean \pm SD; 45.9 ± 10.8) ($p=0.274$) (Figure-4). The ratio of women to men was lower for subjects with RIS that evolved to PPMS than it is in the other two populations (Figure-4).

Accepted Article

DISCUSSION:

This is the first report of the temporal course within the pre-progression phase for an extremely rare group of subjects originally identified by MRI as having asymptomatic disease, who ultimately experienced progressive symptom evolution consistent with PPMS that could not otherwise be explained by any other mechanism (excessive alcohol use, vitamin deficiencies etc). Within the existing scientific literature, only a single case report exists with low resolution MRI evidence of possible MS from an earlier imaging study done 10 years before for unrelated reasons.

21

The 12% prevalence of PPMS in this large RIS cohort, as well as age at PPMS onset, are strikingly similar to that of large clinical studies in MS.¹³ The current RIS diagnostic criteria⁷ appears to be adequately sensitive in identifying potential PPMS patients before they become symptomatic at the same rate as already symptomatic clinic populations, further supporting the growing evidence that RIS, when characterized accurately, is pre-symptomatic MS.¹⁰ Studying RIS, therefore, provides an opportunity to better understand the onset of clinical MS and to test early intervention.

Our current study illustrates that the pre-progressive phase in PPMS is characterized by active but asymptomatic lesion development that is similar to RRMS. For many PPMS patients, being older, male and having a spinal cord dominant lesion load profile is characteristic.¹⁵ We established that just like evolution from RIS to a first acute event related to CNS demyelination consistent with CIS/MS, the strongest predictors of evolution of PPMS included male sex, a more advanced age, and the presence of initially asymptomatic spinal cord disease long before the onset of progressive MS.¹⁰ All subjects that evolved to PPMS in our study had undoubtedly high load of

asymptomatic spinal cord disease in addition to brain lesions fulfilling diagnostic criteria for MS. While we did not observe the often mentioned paucity of brain lesion development in PPMS, this could be driven by our RIS criteria, which biases our study towards the higher brain lesion load patients, or as originally reported, it may be due to the fact that many patients with PPMS indeed have very similar lesion loads to that of bout-onset progressive MS albeit with smaller lesions.²²

Expectedly, subjects who developed symptomatic MS were more likely to have had at least one enhancing lesion on baseline MRI studies when compared to those who remained asymptomatic in the same period. This was independent of development of PPMS or CIS/MS. Subjects who evolved to PPMS were more likely to have had at least one enhancing spinal cord lesion than those who developed CIS/MS or remained asymptomatic. However when corrected for the increased lesion load in the spinal cord for subjects who evolved to PPMS, this difference was not significant. Our findings suggest that the proportion of contrast enhancing lesions are not different between subjects who develop CIS/MS and those who evolve to PPMS during the early pre-symptomatic phase of the disease, suggesting that it is the location of lesion load that seems to make a difference.

In this study, the older age at onset of progressive MS evolving from RIS compared to age at onset of acute clinical events developing in RIS was clearly independent of follow-up times. This age dependence of progressive MS development, in the absence of previous clinical relapses despite having clear sub-clinically active MS, suggests that biological aging mechanisms may be a significant contributor for development of progressive MS. Together with the strikingly similar age-at-onset of the progressive phase of MS, regardless of the presence or absence of acute relapses^{14, 16, 17}, our study suggests that progression mechanisms in PPMS are indeed similar to other progressive MS forms of SAPMS and SPMS.

Furthermore, the progressive disease course contributes strongly, but relatively equally, to the long-term cumulative disability among PPMS, SAPMS and SPMS.²⁰ The difference in long-term cumulative disability outcome among PPMS, SAPMS and SPMS is than explained primarily by the presence or absence of pre-progression clinical manifestations or ongoing clinical relapses after progressive MS onset.²⁰ Ongoing clinically active MS or relapses can be present in 14% of patients after the onset of progressive phase of MS.²⁰ While ongoing relapses after progressive MS onset are less common in patients with PPMS than those with SAPMS or SPMS, when present, the last relapse also remarkably manifests around the same age group in PPMS, SAPMS or SPMS.^{14, 20}

Given similar ages at the onset of progression and termination of relapses, progressive MS patients without preceding clinical relapses likely have subclinical disease activity at similar ages as patients with preceding clinical relapses. This hypothesis needs to be studied further with longer term follow-up of subjects with RIS. The main limitation of our study without doubt is the randomness of the detection of RIS and the difficulty to design a prospective study of natural history of RIS at a population-based level. However, our results are nevertheless intriguing in suggesting that a yet to be defined intervention at RIS phase could potentially delay or ideally prevent PPMS onset.

Together with findings of this study we conclude that subclinical disease activity and progression mechanisms in PPMS, SPMS and SAPMS are likely indistinguishable from each other. The only difference seems to be whether or not active MS manifests clinically as relapses. The relationship between the two relatively specific characteristics of PPMS, resistance to acute clinical relapses and early spinal cord dominance of lesions need to be studied further.

Why some lesions, indistinguishable from their counterparts in symptomatic subjects, never become symptomatic as relapses but still cause enough CNS injury later to lead to progressive disease course remains largely unexplained. Many potential mechanism exist that need to be further studied. These include, but are not limited to, synaptic plasticity exhaustion induced by injury or energy failure due to mitochondrial dysfunction leading to loss of white matter and neuronal integrity maintenance associated with aging.²³⁻²⁶

Accepted Article

ACKNOWLEDGEMENT:

This study was conducted without any specific funding source. We thank the members of the SFSEP/OFSEP and RISC. Please refer to the supplementary table for SFSEP/OFSEP and RISC members.

AUTHOR CONTRIBUTIONS:

Conception and design of the study: OK, CL, AS, DP, DO

Data acquisition and analyses: OK, MS, CL, AS, DP, DO, MK, CA, MI, MT, BN, FDD, MA, NDS

Drafting the manuscript, tables and figures: OK, MS, CL, AS, DP, DO

POTENTIAL CONFLICTS OF INTEREST:

The authors declare no conflicts of interest related to this work.

TABLE 1: Comparative demographics and clinical characteristics of the study population

	Non-converters	All converters	RIS to CIS/MS (15 years)	RIS to PPMS (15 years)	P (CIS/MS vs PPMS)
N	324	128	113	15	NA
F%	81	71	75	40	P [§] = 0.005
Median (yrs) age at RIS (range)	38.6 (14-74)	32.5 (11-70)	32.0 (11-70)	43.3 (20-66)	P [^] < 0.001
Median (yrs) follow-up (range)	2.0 (0-20)	5.2 (0.2-21.1)	5.2 (0.2-21.1)	5.8 (1.1-18.0)	P [^] = 0.66
Median (yrs) time to symptomatic MS* (range)	NA	2.4 (2.0-2.8)	2.3 (1.7-2.9)	3.5 (1.6-5.4)	P ^{**} = 0.21
CSF+(%)	61	75	73	85	P [§] = 0.37
Spinal cord lesions at the time of RIS (%)	23	69	64	100	P [§] = 0.005
(Gd+) spinal cord lesions at the time of RIS (% of all spinal cord lesions)	3.1	17.4	19	27	P [§] = 0.48

§ Chi square test, ^ Mann Whitney U test, *KM estimates, **logrank test; NA= not applicable

Supplementary table-1: SFSEP/OFSEP members in alphabetical order

<i>Name:</i>	<i>Affiliation:</i>
Bertrand Audoin	Hôpital La Timone. Service de Neurologie. 13000 Marseille, France
Caroline Bensa	Fondation Rothchild. Service de Neurologie. 75019 Paris, France
Eric Berger	Hôpital Minjoz. Service de Neurologie. 25000 Besancon. France
David Brassat	Hopital Purpan. Service de Neurologie. 31059 Toulouse, France
Bruno Brochet	Hopital Pellegrin. Service de Neurologie. 33076 Bordeaux, France
Bertrand Bourre	Hopital Charles Nicolle. Service de Neurologie. 76000 Rouen, France
Philippe Cabre	Hopital La Meynard. Service de Neurologie. 97200 Fort de France
Jean-Philippe Camdessanche	Hopital Nord. Service de Neurologie. 42270 SAINT-PRIEST-EN-JAREZ, France
Olivier Casez	Service de Neurologie. 38700. La Tronche France
Giovani Castelnovo	Service de Neurologie. 30029. Nîmes France
Pierre Clavelou	Hopital Montpied. Service de Neurologie. 63003. Clermont Ferrand. France
Nicolas Collongues	Hopital HautePierre. Service de Neurologie. 67100. Strasbourg. France
Marc Coustans	Hopital de Cornouaille. Service de Neurologie. 29000. Quimper. France
Alain Créange	Hopital Mondor. Service de Neurologie. 94000. Creteil France.
Jérôme de Seze	Hopital HautePierre. Service de Neurologie. 67100. Strasbourg. France
Marc Debouverie	Hopital central. Service de Neurologie. 54035 Nancy France
Nathalie Derache	Hopital Cote de Nacre. Service de Neurologie. 14000 Caen France
Gilles Defer	Hopital Cote de Nacre. Service de Neurologie. 14000 Caen France
Dominique Dive	Service de Neurologie. B-4000. Liège Belgique
Francoise Durand-Dubief	Hôpital Neurologique. Service de Neurologie. 69000 BRON. France
Gilles Edan	Hopital Pontchaillou. Service de Neurologie. 35000 Rennes France
Agnès Fromont	Service de Neurologie. 21000 Dijon France
Olivier Gout	Fondation Rothchild. Service de Neurologie. 75019 Paris. France
Riadh Guider	Hopital Razi la Mannouba. Service de Neurologie. Tunis. Tunisie
Jérôme Grimaud	Hopital Fontenou. Service de neurologie. 28360 Le Coudray France
Patrick Hautecoeur	Hopital Saint philibert. Service de Neurologie. 59462 Lomme France

Olivier Heinzlef	Service de Neurologie. 78300 Poissy France
Arnaud Kiatkoswki	Hopital Saint philibert. Service de Neurologie. 59462 Lomme France
Pierre Labauge	Hopital Gui de Chauliac. . Service de Neurologie. 34295. Montpellier France
David Laplaud	Hopital Laennec. Service de Neurologie. 44093. Nantes France
Christine Lebrun-Frénay	Hôpital Pasteur, Service de Neurologie. 06000 Nice, France
Emmanuelle LePage	Hopital Pontchaillou. Service de Neurologie. 35000 Rennes France
Romain Marignier	Hôpital Neurologique. Service de Neurologie. 69000 BRON. France
Thibaut Moreau	Service de Neurologie. 21000 Dijon France
Jean-Christophe Ouallet	Hopital Pellegrin. Service de Neurologie. 33076 Bordeaux, France
Caroline Papeix	Hopital Pitié Salpêtrière. Service de Neurologie. 75010. Paris France
Jean Pelletier	Hôpital La Timone. Service de Neurologie. 13000 Marseille, France
Sophie Pittion,	Hopital central. Service de Neurologie. 54035 Nancy France
Pierrette Seeldrayers	Hopital Marie Curie. Service de Neurologie. Charleroi. Belgique
Ilham Slassi Sennou	Service de Neurologie. Casablanca. Maroc
Bruno Stankoff	Hopital Saint-Antoine. . Service de Neurologie. 75571. Paris France
Frédéric Thaite	Hopital Montpied. Service de Neurologie. 63003. Clermont Ferrand. France
Ayman Tourbah	Hopital Maison Blanche. . Service de Neurologie. 51100 Reims France
Eric Thouvenot	Service de Neurologie. 30029. Nîmes France
Patrick Vermersch	Hopital Salengro. Service de Neurologie. 59037. Lille France
Sandra Vukusic	Hôpital Neurologique. Service de Neurologie. 69000 BRON. France
Sandrine Wiertlewski	Hopital Laennec. Service de Neurologie. 44093. Nantes France
Hélène Zephir	Hopital Salengro. Service de Neurologie. 59037. Lille France

Supplementary table-2: RISC members in alphabetical order

<i>Name:</i>	<i>Affiliation:</i>
Anat Achiron	Sheba Medical Center, Tel-Hashomer, Sackler School of Medicine, Tel-Aviv University, Israel
Ayse Altintas	Istanbul University, Cerrahpasa Department of Neurology. Istanbul, Turkey
Maria Pia Amato	University of Florence, Department of Neurology, Florence, Italy
Christina Azevedo	Keck School of Medicine of the University of Southern California. Department of Neurology. Multiple Sclerosis Center . Los Angeles, California, U.S.A.
Nicola De Stefano	University of Siena, Department of Neurology, Neurosurgery & Behavioral Sciences. Siena, Italy
Stacy Donlon	The CORE Institute, University of Arizona, Phoenix, Arizona
María Inés Gaitán	Neuróloga en Departamento de Neurología, Sección Neuroinmunología y Neurología General, Foundation for Neurological Research, Buenos Aires, Argentina
Le Hua	Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, U.S.A.
Matilde Inglese	Mt. Sinai School of Medicine, New York, New York, U.S.A.
Orhun H. Kantarci	Mayo Clinic College of Medicine, Department of Neurology, Rochester, Minnesota, U.S.A.
Mark B. Keegan	Mayo Clinic College of Medicine, Department of Neurology, Rochester, Minnesota, U.S.A.
Christine Lebrun-Frény	Hôpital Pasteur, Service de Neurologie. Nice, France
Rana Karabudak	Hacettepe University, Department of Neurology. Ankara, Turkey
Farrah Mateen	Harvard Medical School, Boston, Massachusetts, U.S.A.
Darin T. Okuda	University of Texas Southwestern Medical Center, Department of Neurology & Neurotherapeutics, Clinical Center for Multiple Sclerosis, Multiple Sclerosis and NeuroImmunology Imaging Program, Dallas, Texas, U.S.A.
Celia Oreja-Guevara	University Hospital San Carlos, Madrid, Spain
Daniel Pelletier	Keck School of Medicine of the University of Southern California, Department of Neurology, Multiple Sclerosis Center, Los Angeles, California, U.S.A.

Juan Ignacio Rojas	Multiple Sclerosis Center of Buenos Aires (CEMBA), Neurology Department, Buenos Aires, Argentina
Sabahattin Saip	Istanbul University, Cerrahpasa School Medicine, of Neurology. Istanbul, Turkey
Aksel Siva	Istanbul University, Cerrahpasa School of Medicine, Department of Neurology, Istanbul, Turkey
Maria Pia Sormani	University of Genoa, Department of Health Sciences (DISSAL), Genoa, Italy
Mar Tintoré	MS Center of Catalunya Cemcat, Vall d'Hebron Hospital, Barcelona, Spain
Melih Tutuncu	Istanbul University, Cerrahpasa School of Medicine, Department of Neurology. Istanbul, Turkey
Asli Tuncer	Hacettepe University, Department of Neurology. Ankara, Turkey
Ugur Uyguboglu	Istanbul University, Cerrahpasa School of Medicine, Department of Neurology. Istanbul, Turkey
Nrian G. Weinshenker	Mayo Clinic College of Medicine, Department of Neurology, Rochester, Minnesota, U.S.A.

REFERENCES:

1. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. *Ann Neurol*. 2001 Jul;50(1):121-7.
2. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".[see comment]. *Annals of Neurology*. 2005;58(6):840-6.
3. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol*. 2011 Feb;69(2):292-302.
4. Lublin FD. New multiple sclerosis phenotypic classification. *European Neurology*. 2014;72 Suppl 1:1-5.
5. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. *Brain : a journal of neurology*. 1997 Nov;120 (Pt 11):2059-69.
6. Tintore M, Rovira A, Martinez MJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. *AJNR Am J Neuroradiol*. 2000 Apr;21(4):702-6.
7. Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis. The radiologically isolated syndrome. *Neurology*. 2008 Dec 10.
8. Lebrun C, Bensa C, Debouverie M, et al. Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. *J Neurol Neurosurg Psychiatry*. 2008 Feb;79(2):195-8.
9. Siva A, Saip S, Altintas A, Jacob A, Keegan BM, Kantarci OH. Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease. *Multiple Sclerosis*. 2009 Aug;15(8):918-27.

10. Okuda DT, Siva A, Kantarci O, et al. Radiologically isolated syndrome: 5-year risk for an initial clinical event. *PloS one*. 2014;9(3):e90509.
11. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. *Neurology*. 1996 Apr;46(4):907-11.
12. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. *Brain*. 2006 Mar;129(Pt 3):584-94.
13. Kantarci O, Siva A, Eraksoy M, et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). *Neurology*. 1998 Sep;51(3):765-72.
14. Tutuncu M, Tang J, Zeid NA, et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. *Multiple Sclerosis*. 2013 Feb;19(2):188-98.
15. Thompson A. Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis. *Mult Scler*. 2004 Jun;10 Suppl 1:S2-7.
16. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. *Brain*. 2006 Mar;129(Pt 3):606-16.
17. Koch M, Mostert J, Heersema D, De Keyser J. Progression in multiple sclerosis: further evidence of an age dependent process. *J Neurol Sci*. 2007 Apr 15;255(1-2):35-41.
18. Siva A, Radhakrishnan K, Kurland LT, et al. Trauma and multiple sclerosis: a population-based cohort study from Olmsted County, Minnesota. *Neurology*. 1993 Oct;43(10):1878-82.
19. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. *Ann Neurol*. 2004 Aug;56(2):303-6.
20. Paz Soldan MM, Novotna M, Abou Zeid N, et al. Relapses and disability accumulation in progressive multiple sclerosis. *Neurology*. 2015 Jan 6;84(1):81-8.

21. McDonnell GV, Cabrera-Gomez J, Calne DB, Li DK, Oger J. Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions: the subclinical stage of primary progressive multiple sclerosis may last 10 years. *Mult Scler.* 2003 Mar;9(2):204-9.
22. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. *Ann Neurol.* 1991 Jan;29(1):53-62.
23. Mori F, Rossi S, Piccinin S, et al. Synaptic plasticity and PDGF signaling defects underlie clinical progression in multiple sclerosis. *J Neurosci.* 2013 Dec 4;33(49):19112-9.
24. Campbell GR, Worrall JT, Mahad DJ. The central role of mitochondria in axonal degeneration in multiple sclerosis. *Multiple sclerosis.* 2014 Dec;20(14):1806-13.
25. Westlye LT, Walhovd KB, Dale AM, et al. Life-span changes of the human brain white matter: diffusion tensor imaging (DTI) and volumetry. *Cereb Cortex.* Sep;20(9):2055-68.
26. Hasan KM, Kamali A, Abid H, Kramer LA, Fletcher JM, Ewing-Cobbs L. Quantification of the spatiotemporal microstructural organization of the human brain association, projection and commissural pathways across the lifespan using diffusion tensor tractography. *Brain structure & function.* May;214(4):361-73.

FIGURE LEGENDS:

Figure-1: Structure of the study populations. MS= multiple sclerosis, PPMS = primary progressive multiple sclerosis.

Figure-2: An example of a subject with RIS that has been followed for 9 years before developing PPMS. The multiple active but asymptomatic lesions that have evolved during this time indistinguishable from any RRMS patient are illustrated. The notable spinal cord atrophy in later follow-up MRIs is in keeping with the clinically observed progressive myelopathy and ataxia is shown.

Figure-3: Age at and time to evolution from RIS to PPMS or CIS/MS are shown

Figure-4: Age at onset of progressive MS distribution in; RIS evolving to PPMS, population-based PPMS and clinic-based PPMS cohorts is shown




Figure-1 in BW
1058x793mm (96 x 96 DPI)

Accept




Figure-2 in BW
1058x793mm (96 x 96 DPI)

Accept




Figure-3 in BW
1058x793mm (96 x 96 DPI)

Accept




Figure-4 in BW
1058x793mm (96 x 96 DPI)

Accept